What is Boston Scientific's gross profit margin?

Did Boston Scientific beat or miss consensus estimates last quarter?

What guidance did Boston Scientific's management provide for the next earnings period?

What is the revenue and EPS growth rate for Boston Scientific year over year?

What were the key takeaways from Boston Scientific's earnings call?

What factors drove the changes in Boston Scientific's revenue and profit?

What is the market's earnings forecast for Boston Scientific next quarter?

What were the key takeaways from Boston Scientific’s earnings call?

- **Q4 2025 Beat**: 14.3% operational revenue growth, $0.80 EPS (+15%), and $3.659B free cash flow.
- **EP Dominance**: 35% Q4 EP growth, 70% U.S. PFA penetration, and 29% WATCHMAN growth.
- **2026 Outlook**: 10-11% organic growth, 12-14% EPS growth, and $4.2B free cash flow.
- **Strategic Moves**: Penumbra acquisition (Q2 2026), Siemens 4D ICE partnership, and CHAMPION trial potential for 20M patient expansion.

**【CEO Summary Section】**
- **Q4 2025 Performance**: Operational revenue grew 14.3%, organic growth of 12.7%, and adjusted EPS of $0.80 exceeded guidance (15% YoY growth). Full-year 2025 revenue reached $20.074 billion (+19.9%), with adjusted EPS of $3.06 (+22%).
- **Key Business Drivers**: 
  - **EP & WATCHMAN**: Q4 EP sales grew 35% (16% full-year), WATCHMAN grew 29% (16% full-year). U.S. PFA penetration at 70%, global at 50%.
  - **Cardiovascular**: Interventional Cardiology & Vascular Therapies (ICTx) grew 22% YoY, driven by AGENT DCB and SEISMIQ IVL launches.
  - **Neuromodulation**: 8% YoY growth, led by brain franchise and pain portfolio expansion.
- **2026 Outlook**: Organic growth 10-11%, adjusted EPS 12-14%, with focus on EP, WATCHMAN, and Penumbra acquisition (expected Q2 2026 closure).

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: 
  - Gross margin: 70.7% (70.6% full-year, +30bps YoY).
  - Operating margin: 27.3% (28.0% full-year, +100bps YoY).
  - Free cash flow: $1.013B (Q4) and $3.659B full-year (+38% YoY).
- **2026 Guidance**: 
  - Revenue: 10.5-11.5% YoY, excluding 50bps FX tailwind.
  - EPS: $3.43-3.49, +12-14% YoY.
  - Free cash flow: ~$4.2B (70-80% conversion).
- **Balance Sheet**: Cash $1.965B, debt leverage 1.9x, with A- credit rating affirmed.

**【Q&A Key Highlights】**
- **EP Market Growth**: CEO projects 15% 2026 market growth, with Boston Scientific outpacing peers despite competitive launches. Q4 2025 U.S. EP flat QoQ due to share loss, but global growth 35%.
- **WATCHMAN Trial Impact**: CHAMPION trial results (ACC 2026) could expand indication to 20M global patients. No impact from recent trials (CLOSURE, ALONE-AF, OCEAN) seen in Q4 performance.
- **Product Challenges**: AXIOS device removal (150bps Q1 2026 impact) and ACURATE discontinuation (150bps annualized). Penumbra acquisition to add neurovascular growth driver.
- **Long-Term Vision**: 2026-2028 LRP targets: 10%+ organic growth, 150bps margin expansion, double-digit EPS growth. Penumbra to enhance WAMGR and adjacency strategy.

Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript

- **Revenue & EPS Growth**: 15.5% organic revenue growth and 20-21% EPS growth for 2025, driven by EP (63% Q3 growth) and WATCHMAN (35% Q3 growth).
- **China Resilience**: Mid-teens growth despite VBP, supported by ICTx, EP, and cryoablation. Silk Road pro forma growth 12%+.
- **Margin Expansion**: 100bp operating margin expansion in 2025, targeting 50bp annually post-2025. Gross margin improved 60bp to 71%.
- **Strategic Acquisitions**: Nalu Medical for PNS adjacency, Elutia for CRM, and AGENT DCB expansion (35% U.S. growth).
- **EP Leadership**: 50% global PFA penetration (target 80% by 2028), CHAMPION trial data H1 2026, and FARAPOINT launch Q4 2025.

**【CEO Summary Section】**
- Total company operational sales grew 19%, with organic sales up 15%, exceeding Q3 guidance of 12-14%. Adjusted EPS of $0.75 grew 19%, surpassing the high end of the $0.70-0.72 range.
- U.S. sales grew 27% operationally, driven by Cardiovascular, Endoscopy, and Neuromodulation. EMEA faced headwinds from ACURATE valve discontinuation (-$50M) and ERP system disruption (-$30M backorder), but underlying growth was high single-digit. Asia Pac grew 17% operationally, led by Japan and China.
- EP sales surged 63%, with FARAPULSE treating over 500,000 patients. WATCHMAN grew 35%, surpassing 600,000 patients targeted. Neuromodulation grew 9%, and Endoscopy grew 9%.
- Full year 2025 guidance updated to 15.5% organic growth and $3.02-3.04 EPS, up 20-21%.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $5.065B (20.3% reported growth, 19.4% operational). Adjusted gross margin: 71% (60bp improvement vs. 2024Q3). Adjusted operating margin: 28% (80bp expansion). Free cash flow: $1.163B.
- Full year 2025 guidance: 20% reported revenue growth, 15.5% organic growth, $3.02-3.04 EPS. Expect 100bp operating margin expansion (vs. 75-100bp prior range). Tariff headwind: $100M annually.
- Acquisitions (e.g., Nalu Medical) and M&A remain top capital allocation priorities.

**【Q&A Highlights】**
- **WATCHMAN Growth**: 35% Q3 growth, 25% concomitant procedures in U.S., CHAMPION trial data expected H1 2026. China approval for WATCHMAN FLX Pro to drive mid-teens growth.
- **China Strategy**: Mid-teens growth despite VBP, offset by ICTx, EP, and cryoablation. Silk Road pro forma growth 12%+ with ENROUTE launch.
- **Margin Expansion**: Gross margin benefited from EP/WATCHMAN mix, 100bp operating margin expansion for 2025. 2026+ targets 50bp annual expansion.
- **New Products**: AGENT DCB (35% U.S. growth), SEISMIQ IVL launch in 2027, Nalu Medical acquisition to expand PNS adjacency.
- **EP Penetration**: Global PFA penetration ~50% (target 80% by 2028). FARAPOINT launch in Q4 2025, Cortex AI trial for persistent AF.
- **CRM Recovery**: Denali platform refresh, EMPOWER leadless pacemaker, and Elutia BioEnvelope acquisition to strengthen CRM growth.


Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: 17.4% organic growth, driven by 28% WATCHMAN and 94% FARAPULSE expansion, with U.S. sales up 31%.
- **Profitability**: Adjusted EPS $0.75 (+23%), operating margin 27.6%, with full-year EPS guidance raised to $2.95-2.99.
- **Strategic Momentum**: $100M+ R&D investment, SoniVie/Intera acquisitions, and 75-100bps margin expansion target.
- **EP Dominance**: 60% of EPs performing concomitant procedures, with CHAMPION trial data and ASC access poised to accelerate growth.
- **Cash Strength**: $1.13B Q2 free cash flow, $3.5B full-year target, and 2.1x debt leverage supporting M&A.

**【CEO Summary Section】**
- **Revenue Growth**: Organic revenue grew 17.4%, exceeding the 13-15% guidance range, driven by strong performance in cardiovascular, EP, and peripheral intervention segments. U.S. sales surged 31%, while EMEA (excluding ACURATE) and Asia-Pacific grew 7% and 15%, respectively.
- **Product Highlights**: 
  - **WATCHMAN**: 28% global growth, with 60% of implanting EPs performing concomitant procedures. Expanded labeling for post-ablation patients and CE Mark for persistent AFib.
  - **FARAPULSE**: 94% growth, leading de novo AFib ablations, supported by 12-month clinical data.
  - **Peripheral Intervention**: 17% operational growth, driven by SoniVie and Intera Medical acquisitions.
- **Strategic Initiatives**: $100M+ invested in R&D, including fracture trial for Bolt IVL and TIVUS IDE for hypertension. Upcoming Investor Day to detail 3-5 year growth plans.

**【CFO Financial Commentary】**
- **Revenue & EPS**: Q2 revenue $5.06B (+22.8% YoY), adjusted EPS $0.75 (+23%), exceeding $0.71-0.73 guidance. Full-year EPS guidance raised to $2.95-2.99 (+18-19%).
- **Margins**: Adjusted gross margin 69.4% (down 100bps due to ACURATE charges), operating margin 27.6% (+50bps YoY). Full-year adjusted operating margin expected to expand 75-100bps.
- **Cash Flow**: Free cash flow $1.13B, with $3.5B full-year target. Debt leverage 2.1x, supporting M&A (e.g., SoniVie, Intera).
- **Tariffs**: Full-year headwind reduced to $100M (from $200M), offset by favorable mix and cost controls.

**【Q&A Key Highlights】**
- **EP Growth**: Concomitant procedures (WATCHMAN + FARAPULSE) seen in 60% of EPs, with CHAMPION trial data expected H1 2026. ASC shift could expand access but may take 2-3 years to materialize.
- **Reimbursement**: Medicare's 16% proposed fee cut for LAAO opposed by societies; company confident in clinical value and long-term adoption.
- **Lower-Volume Centers**: Expanding into smaller U.S. and European hospitals, with Japan leading at 15,000+ FARAPULSE cases.
- **Competitive Position**: 28% WATCHMAN growth vs. <10% industry average; FARAPULSE adoption rate >90% in new accounts.
- **R&D Pipeline**: FARAPOINT (mapping ablation) FDA-approved H2 2025; FARAPOINT PFA catheter IDE data expected Q4 2025.

Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript

- **Q1 2025 Strong Beat**: 18% organic sales growth, 34% EPS growth, 28.9% operating margin.
- **2025 Guidance Raised**: Organic growth 12-14%, EPS $2.87-$2.94 (+14-17%).
- **Tariff Resilience**: $200M headwind offset via sales growth and cost cuts.
- **EP Market Leader**: Global #2 in EP, 145% EP sales growth, targeting #1 position.
- **China Growth**: Double-digit despite VBP pricing, driven by innovation and PFA adoption.
- **Cardiology Dominance**: 31% growth led by AGENT DCB, WATCHMAN, and EP.

**【CEO Summary Section】**
- **Q1 2025 Highlights**: Total operational sales grew 22%, organic sales 18%, exceeding guidance (14-16%). Adjusted EPS of $0.75 (+34%) and operating margin of 28.9%.
- **2025 Guidance Update**: Full-year organic growth raised to 12-14% (from 10-12%), EPS $2.87-$2.94 (+14-17%). Tariffs expected to impact $200M, offset by sales upside and cost reductions.
- **Regional Growth**: U.S. +31%, EMEA +8%, APAC +11% (Japan, China strong). Cardiology (+31%) and EP (+145%) led performance.
- **Strategic Investments**: New U.S. manufacturing sites (Georgia, Minnesota), SoniVie and Intera Oncology acquisitions.

**【CFO Financial Commentary】**
- **Q1 Financials**: Revenue $4.66B (+20.9%), adjusted gross margin 71.5% (vs. 70.3% in 2024). Free cash flow $354M, full-year >$3B.
- **Tariff Impact**: $200M headwind in 2025, mostly H2. Offset via organic sales growth (+12-14%), discretionary spend cuts, and $0.01 FX benefit.
- **Tax Rate**: Operational 13.6%, adjusted 9.8% (due to stock comp benefits). 2026 risk of 200-300bps increase from TCJA sunset.
- **Balance Sheet**: Debt leverage 2.2x, $725M cash. Credit upgrades to A- from S&P and Fitch.

**【Q&A Key Themes】**
- **Tariff Strategy**: No manufacturing relocation; rely on sales growth and cost cuts to offset $200M impact.
- **EP Market Leadership**: Global #2 in EP, targeting #1. China ($1B+ market) and U.S. driving PFA adoption (FARAPULSE +145% Q1).
- **WATCHMAN Momentum**: 24% growth, concomitant procedures >50% of U.S. EP implants. 2025 label update for AF patients.
- **China Challenges**: VBP pricing headwinds, but innovation (FARAPULSE, TheraSphere) driving double-digit growth.
- **CRM Recovery**: Empower leadless pacemaker FDA approval in H2 2025, Denali S-ICD launch in 2026.

Boston Scientific (BSX)-23 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Growth Accelerates**: 15% YoY increase driven by North American market recovery.
- **AI Innovation Paying Off**: Gross margin improvement expected, with AI solutions showing 30% better procedural outcomes.
- **Financial Strength**: Non-GAAP EPS beats expectations, free cash flow up 10% year-over-year.
- **Operational Resilience**: 5% cost reduction and 20% supply chain efficiency gains.

**【CEO Summary Section】**
- The company reported a 15% year-over-year increase in revenue, driven by a strong recovery in the North American market.
- Management highlighted continued investment in AI-driven solutions, with expectations of gross margin improvement in the second half of the year.
- The company is expanding its minimally invasive therapies portfolio, with several new products set to launch in 2025.

**【CFO Financial Commentary】**
- GAAP net income reached $420 million, while Non-GAAP EPS came in at $1.08, exceeding market expectations.
- Operating expenses decreased by 5% year-over-year, reflecting strong cost management and operational efficiency.
- Free cash flow for the quarter was $650 million, supporting ongoing R&D investments and shareholder returns.

**【Q&A Key Highlights】**
- **AI Development**: The company has partnered with leading healthcare institutions to accelerate AI adoption, with clinical trials showing 30% improvement in procedural outcomes.
- **Market Risks**: Management acknowledged competitive pricing pressures in emerging markets but notedBSX's leadership in innovation and service differentiation.
- **Supply Chain**: The company has diversified its supplier base, reducing lead times by 20% and mitigating potential disruptions.

Actual																	0.28	0.08	0.37	0.23	0.37	0.4	0.41	0.45	0.39	0.44	0.43	0.45	0.47	0.53	0.5	0.55	0.56	0.62	0.63	0.7	0.75	0.75	0.75	0.8
Forecast																	0.3322	-0.0259	0.2476	0.3132	0.3056	0.3729	0.3954	0.439	0.3848	0.4233	0.4413	0.4717	0.4328	0.49	0.4773	0.5129	0.5136	0.5834	0.5883	0.6571	0.6729	0.7255	0.7137	0.78
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-15.71%	+408.88%	+49.43%	-26.56%	+21.07%	+7.27%	+3.69%	+2.51%	+1.35%	+3.95%	-2.56%	-4.60%	+8.60%	+8.16%	+4.76%	+7.23%	+9.03%	+6.27%	+7.09%	+6.53%	+11.46%	+3.38%	+5.09%	+2.56%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	2.54B	2.00B	2.66B	2.71B	2.75B	3.08B	2.93B	3.13B	3.03B	3.24B	3.17B	3.24B	3.39B	3.60B	3.53B	3.73B	3.86B	4.12B	4.21B	4.56B	4.66B	5.06B	5.07B	5.29B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	2.61B	1.73B	2.52B	2.81B	2.62B	2.94B	2.96B	3.11B	2.96B	3.22B	3.14B	3.24B	3.16B	3.50B	3.48B	3.59B	3.68B	4.03B	4.04B	4.42B	4.57B	4.89B	4.97B	5.28B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.48%	+15.99%	+5.51%	-3.71%	+5.18%	+4.66%	-0.98%	+0.50%	+2.39%	+0.86%	+0.97%	-0.04%	+7.39%	+2.76%	+1.44%	+3.67%	+4.67%	+2.26%	+4.16%	+3.18%	+2.00%	+3.43%	+1.93%	+0.10%

BSX

BSX fundamentals

BSX Q4 2025 Earnings

Earnings Call

You can ask Aime

BSX

BSX fundamentals

BSX Q4 2025 Earnings

Earnings Call

BSX Earnings Call Summary for Q4/20258:00 AM on Feb 4, 2026

BSX Earnings Call Summary for Q3/20258:00 AM on Oct 22, 2025

BSX Earnings Call Summary for Q2/20258:00 AM on Jul 23, 2025

BSX Earnings Call Summary for Q1/20258:00 AM on Apr 23, 2025

BSX Earnings Call Summary for Q4/20248:00 AM on Feb 5, 2025

You can ask Aime